ライフサイエンスコーパス: teduglutide

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ents with SBS-IF who were given subcutaneous teduglutide (0.05 mg/kg/d; n = 43) or placebo (n = 43) o

2 , 14 women) to receive subcutaneous doses of teduglutide 4 mg or placebo (2:1 ratio; 23:13) once dail

3 ere observed on Day 10 in subjects receiving teduglutide 4 mg versus subjects receiving placebo.

4 Teduglutide 4 mg/day for 10 days does not affect gastric

5 Teduglutide, a glucagon-like peptide 2 analogue, might r

6 Teduglutide, a recombinant analog of human glucagon-like

7 with SBS support the safety and efficacy of teduglutide as an aid to parenteral nutrition weaning.

8 ed for parenteral support was greater in the teduglutide group (21/39 [54%]) than in the placebo grou

9 re were significantly more responders in the teduglutide group (27/43 [63%]) than the placebo group (

10 eduction in parenteral support volume in the teduglutide group was 4.4 +/- 3.8 L/wk (baseline 12.9 +/

11 Teduglutide had an intermediate effect on patients in gr

12 identify characteristics of patients in whom teduglutide has the largest effects on parenteral suppor

13 The effects of mitogenic stimulation with teduglutide in patients with short bowel syndrome might

14 Teduglutide increased bromodeoxyuridine-positive cells v

15 Teduglutide increased Caco-2 proliferation but tended to

16 The MTS assay demonstrated that teduglutide increased cell numbers by a mean (SD) of 10%

17 Teduglutide increased plasma concentrations of citrullin

18 Teduglutide is a recombinant analogue of human glucagonl

19 the intestinal mucosa, and a GLP-2R agonist, teduglutide, is now used for augmentation of energy abso

20 tinuation was similar between patients given teduglutide (n = 2) and placebo (n = 3).

21 The effects of teduglutide on absolute parenteral support volume were s

22 ve of this study was to assess the effect of teduglutide on gastric emptying of liquids in healthy su

23 However, the effects of teduglutide on parenteral support vary among patients.

24 ata from a phase III study of the effects of teduglutide on patients with SBS, we associated reduced

25 tabolism classification system, who received teduglutide or placebo between November 25, 2008, and Ja

26 etaminophen absorption in subjects receiving teduglutide or placebo.

27 Cells were exposed to teduglutide or vehicle control.

28 Teduglutide reduced the mean (SD) expression of villin b

29 med a prospective study to determine whether teduglutide reduces parenteral support in patients with

30 BACKGROUND & AIMS: Clinical studies showed teduglutide to increase urine production and reduce need

31 ndrome might be greater if the more numerous teduglutide-treated cells could be stimulated toward a m

32 436 mL/d; P = .0112) but also compared with teduglutide-treated patients in group 2 (reduction of 35

33 ted parenteral support volume reduction with teduglutide treatment and baseline parenteral support vo

34 Twenty-four weeks of teduglutide treatment was generally well tolerated in pa

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。